Competition Bureau completes preliminary investigation of relabelled biologic drugs* The Competition Bureau has completed its preliminary investigation into potential anti-competitive harm from relabelled biologic drugs. Relabelled biologic drugs are identical to originator biologic drugs but marketed under a secondary brand name.
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.